CBIO earnings date and last-quarter result: next report 2026-07-30, last quarter beat, P/E -1.45. Updated 2026-07-23.
Crescent Biopharma (CBIO) Research Hub
Crescent Biopharma (CBIO) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 12.76 USD (-0.47%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.45, market cap 0.43B. This hub links to the full technical, earnings and options research available for CBIO.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 12.76 USD (-0.47%) |
| 52-week range | 11.78 USD – 22.33 USD |
| Trend regime | Range |
| 14-day RSI | 43.6 (Bearish) |
| Trailing P/E | -1.45 |
| Market cap | 0.43B |
| Dividend yield | 0.00% |
| Next earnings | 2026-07-30 |
Available research for CBIO
Covered Call on CBIO: how it works, illustrative setup around the real 12.76 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on CBIO: how it works, illustrative setup around the real 12.76 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on CBIO: how it works, illustrative setup around the real 12.76 USD price, max profit/loss, breakeven and when to use it. Educational.
CBIO technical analysis: range, last 12.76 USD, RSI 43.6, 52w range 11.78 USD–22.33 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is CBIO in?
Crescent Biopharma (CBIO) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is CBIO in an uptrend or downtrend?
As of 2026-10-26, CBIO is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is CBIO's trailing P/E ratio?
CBIO's trailing P/E is -1.45, with a market cap of 0.43B. See the earnings research page for full valuation detail.
When does CBIO next report earnings?
CBIO is next scheduled to report earnings on 2026-07-30.